Hangzhou Primo Biotechnology Co., Ltd. (hereinafter referred to as Primo Biotechnology), a microbial biopharmaceutical enterprise focusing on the research and development of autoimmune diseases, recently completed its first round of financing. This financing was exclusively invested by Xinghua Dingli Venture Capital, with an investment amount exceeding 10 million yuan. Puyuan Bio said that the funds obtained from the financing will be used for further functional development and clinical research of its own strains such as PM002 and PM005, market development of its own probiotic brand Gibson, and the construction of a fermentation center.
Puyuan Biotech was founded in April 2021 by Professor Liang Qiming from Shanghai Jiaotong University School of Medicine. Professor Liang Qiming has more than ten years of experience in biomedical research and development. He has long been committed to the mechanism and transformation of microbial infection and immunity, and has identified multiple strains of probiotics that regulate autoimmune diseases. Under the leadership of Professor Liang Qiming, based on the research of microbiome, Probiotics focuses on the frontiers of neuroimmunity and intestinal flora, and develops and produces probiotics and their products. At present, the company has mastered the technologies of strain characteristics research and large-scale preparation, and has adopted fermentation liquid membrane filtration technology to achieve high-density fermentation and concentration. On the other hand, pretreatment with cold shock and optimized protective agent can make the survival rate of probiotics freeze-dried reach 95%, and the concentration of viable bacteria can reach as high as 1012 CFU/g.
On the basis of in-depth research on the impact of intestinal flora on the autoimmune system, the company uses microecological preparations to regulate intestinal flora, regulate the immune homeostasis of the human body, and master a series of new ways to prevent and treat autoimmune diseases. At present, Puyuan Biotechnology has established a “localized” functional strain library, and deployed tens of thousands of strain resources. Among them, there are more than 2,500 strains with excellent characteristics of independent intellectual property rights. Multiple strains for sclerosis, ankylosing spondylitis, tumor immunity, diabetes and other indications.
Yang Zhenhuan, investment director of Biomedicine, said: “Microbial biomedicine is widely used and has a broad market. The interaction mechanism between various species of human microorganisms is constantly being revealed, and innovative results have been emerging. With the end of last year, the world’s first fecal microbial therapy The live biopharmaceutical industry is about to enter an explosive period. Relying on the rich probiotic resource bank and excellent research and development capabilities, the Probiotics team has independently developed a number of star strains around the field of autoimmunity, and the early experimental results are exciting. We are firmly optimistic about the prospects of this field and the development potential of Primobiology, and look forward to the steady and long-term development of Primobiology and become a leading company in living biological medicine.”
attached
To view more project information, please go to “Smart Beast Analysis” .
media reports
Arterial Network Arterial Network Entrepreneurship State
related events
- Puyuan Biotech completed the first round of financing exceeding 10 million yuan2023-01-19
- Ketaiya Biological completed the A+ round of financing exceeding RMB 100 million2022-11-07
- Anaerobic Biotech completed the A-round financing of 100 million yuan2022-08-01
- “Hengyu Biological” completed the A+ round of financing, and Guofang Capital led the investment2022-07-25
- Taichuang received more than 100 million US dollars in A+ round financing2022-03-14
This article is transferred from: https://readhub.cn/topic/8mH82lh4BOL
This site is only for collection, and the copyright belongs to the original author.